Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by BILLINGS, R.
Right arrow Articles by DONOVAN, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BILLINGS, R.
Right arrow Articles by DONOVAN, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1975 British Society for Rheumatology

research-article

A DOUBLE-BLIND CROSS-OVER TRIAL OF PRENAZONE* AND ASPIRIN IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS

R. BILLINGS{dagger}, H. C. BURRY{dagger}, R. GRAHAME{dagger}, D. J. BERRY{ddagger} and B. DONOVAN§

{dagger}The Guy's Arthritis Research Unit, Guy's Hospital London SE1 9RT
{ddagger}Poisons Unit, New Cross Hospital London SE14
§General Practitioner Camberley, Surrey

A double-blind cross-over trial of Prenazone 600 mg and Aspirin 4 g daily was carried out on 20 patients suffering with rheumatoid arthritis. The analgesic and anti-inflammatory activity was indistinguishable from that of aspirin under the conditions of the trial. Twelve patients expressed a general preference for Prenazone and six for aspirin. Prenazone appeared to be well tolerated and free from serious side-effects. These results suggest that it will be a useful drug in the management of rheumatoid arthritis.

*INN now Feprazone.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.